Cepheid is a leading molecular diagnostics company dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases.
Over a decade ago, the organisation set the standard for innovation in automated molecular diagnostics — and never looked back. Today, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving its capabilities. The GeneXpert® System has been heralded as game-changing by healthcare leaders across the globe — enabling institutions of any size, from small medical clinics to high volume reference laboratories and hospitals, to access the speed and accuracy of molecular diagnostics. Cepheid’s growing Xpert® test menu spans multiple clinical applications including healthcare associated infections, sexual health, critical infectious disease, virology, and oncology
Cepheid’s mission is to deliver a better way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere. With a multi-decade track record of expertise and innovation, the company is focusing on those applications where accurate, rapid, and actionable results are needed most – including respiratory, sexual health, critical infectious diseases, and oncology.
For many years, Cepheid has made a positive impact on the lives of millions with the help of the innovative GeneXpert® system (CBNAAT) and revolutionary Xpert® MTB/RIF* Test.
The organisation started working with the GoI through the NTEP which adopted the GeneXpert System in 2015 to test TB, which is also known as the Cartridge Based Nucleic Acid Amplification Test (CBNAAT) for the critical diagnosis of tuberculosis (TB) and first-line drug resistance using Xpert® MTB/RIF. Until now, Cepheid India has touched upon more than 10 million people in India through its revolutionary Xpert MTB/RIF test at the government-identified TB centers and at various other hospitals and laboratories across India to detect TB and associated drug resistance.
Cepheid operates within the Danaher family of operating companies. With a patient-centric approach, the company is striving to deliver the benefits of seamlessly accessible molecular testing closer to the patient, enabling a higher quality of care, lower costs, and improved outcomes. Visit www.cepheid.com to view our entire portfolio of molecular diagnostic tests and systems.